Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Thromboxane (TXA2) activates the T prostanoid (TP) receptor. Prostaglandin E2 (PGE2) activates four E prostanoid (EP) receptors, EP1-4. AH 23848 is a dual antagonist of TP and EP4 receptors.1,2 It originally was found to inhibit TXA2-induced platelet aggregation (IC50 = 0.26 μM) and the contraction of human bronchial smooth muscle induced by the TP agonist U-46619.1,3 AH 23848 was subsequently demonstrated to impair PGE2-mediated relaxation of piglet saphenous vein by antagonizing the PGE2 receptor EP4.2 By inhibiting EP4, it likewise suppresses serum-induced cAMP generation, cyclin A synthesis, and the proliferation of fibroblasts, as well as reduces metastasis in a mouse model of metastatic breast cancer.4,5
WARNING This product is not for human or veterinary use.
1. AH23848: A thromboxane receptor-
2. A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins 47, 151-168 (1994).
3. Prostanoid-
4. Role of EP1 and EP4 PGE2 subtype receptors in serum-
5. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res. 66(6), 2923-2927 (2006).